Burke R E, Fahn S, Mayeux R, Weinberg H, Louis K, Willner J H
Neurology. 1981 Aug;31(8):1022-5. doi: 10.1212/wnl.31.8.1022.
Prior reports of neuroleptic malignant syndrome (NMS) concerned patients with psychiatric disorders, usually schizophrenia, who were taking dopamine receptor blocking agents. We report the syndrome in a patient with Huntington disease who was treated with dopamine-depleting agents. He had a negative evaluation for malignant hyperthermia (MH), and we suggest that NMS differs from MH. The occurrence of NMS caused by dopamine-depleting agents suggests that anticholinergic properties of phenotiazines are not the only cause. Central dopaminergic systems probably participate in thermoregulation, and dopamine depletion probably plays a pathogenetic role in this syndrome.
先前有关抗精神病药恶性综合征（NMS）的报告涉及患有精神疾病（通常为精神分裂症）且正在服用多巴胺受体阻断剂的患者。我们报告了1例患有亨廷顿病且接受了多巴胺耗竭剂治疗的患者出现该综合征。他的恶性高热（MH）检查结果为阴性，我们认为NMS与MH不同。由多巴胺耗竭剂引起的NMS表明，吩噻嗪类药物的抗胆碱能特性并非唯一病因。中枢多巴胺能系统可能参与体温调节，多巴胺耗竭可能在该综合征中起致病作用。
